|
|||||
|
|
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer |
|
| Authors: | Tindall Donald J Rittmaster Roger S |
| Affiliation: | Mayo Clinic, Rochester, Minnesota, and GlaxoSmithKline (RSR), Research Triangle Park, North Carolina |
| Abstract: | |
| Keywords: | prostate prostatic neoplasms cholestenone 5 alpha-reductase androgens dihydrotestosterone |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |